OwlTail

Cover image of Roy H. Decker

Roy H. Decker

6 Podcast Episodes

Latest 28 Aug 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Roy H. Decker, MD, PhD - NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/YKQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the role of immunotherapy in multimodal management of locally advanced and early-stage lung cancer. Upon completion of this activity, participants should be better able to: Discuss how to harness the immune system in the treatment of cancer, mechanisms of action of immune checkpoint inhibitors, and rationale for use of immunotherapy in locally advanced and earlier stages of lung cancer in the context of other treatment modalities, including chemotherapy, radiotherapy, and surgery, Evaluate key clinical trial data on the efficacy and safety of immune checkpoint inhibitor–based treatment in patients with unresectable stage III NSCLC whose cancer has not progressed following concurrent chemoradiation, Summarize other key clinical trials evaluating immunotherapies and immunotherapy-based combinatorial approaches in earlier stages of lung cancer, and available evidence from these trials, Identify appropriate patients with locally advanced, unresectable NSCLC who are candidates for immunotherapy as part of multimodal therapy for stage III disease, Implement an optimal multimodal treatment plan inclusive of concurrent chemoradiotherapy and consolidation immunotherapy for appropriate patients with stage III NSCLC, considering the latest evidence, indications, recommendations, and patient needs/preferences, Manage overlapping and non-overlapping adverse effects associated with immunotherapy, radiation therapy, and chemotherapy in patients with stage III NSCLC receiving consolidation therapy with a checkpoint inhibitor following chemoradiation

1hr 10mins

4 Nov 2019

Episode artwork

Roy H. Decker, MD, PhD - NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/YKQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the role of immunotherapy in multimodal management of locally advanced and early-stage lung cancer. Upon completion of this activity, participants should be better able to: Discuss how to harness the immune system in the treatment of cancer, mechanisms of action of immune checkpoint inhibitors, and rationale for use of immunotherapy in locally advanced and earlier stages of lung cancer in the context of other treatment modalities, including chemotherapy, radiotherapy, and surgery, Evaluate key clinical trial data on the efficacy and safety of immune checkpoint inhibitor–based treatment in patients with unresectable stage III NSCLC whose cancer has not progressed following concurrent chemoradiation, Summarize other key clinical trials evaluating immunotherapies and immunotherapy-based combinatorial approaches in earlier stages of lung cancer, and available evidence from these trials, Identify appropriate patients with locally advanced, unresectable NSCLC who are candidates for immunotherapy as part of multimodal therapy for stage III disease, Implement an optimal multimodal treatment plan inclusive of concurrent chemoradiotherapy and consolidation immunotherapy for appropriate patients with stage III NSCLC, considering the latest evidence, indications, recommendations, and patient needs/preferences, Manage overlapping and non-overlapping adverse effects associated with immunotherapy, radiation therapy, and chemotherapy in patients with stage III NSCLC receiving consolidation therapy with a checkpoint inhibitor following chemoradiation

1hr 10mins

4 Nov 2019

Similar People

Episode artwork

Roy H. Decker, MD, PhD - NSCLC Tumor Board: Navigating the Evolving Role of Immunotherapy in Multimodal Management of Locally Advanced and Early-Stage Lung Cancer

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/YKQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the role of immunotherapy in multimodal management of locally advanced and early-stage lung cancer. Upon completion of this activity, participants should be better able to: Discuss how to harness the immune system in the treatment of cancer, mechanisms of action of immune checkpoint inhibitors, and rationale for use of immunotherapy in locally advanced and earlier stages of lung cancer in the context of other treatment modalities, including chemotherapy, radiotherapy, and surgery, Evaluate key clinical trial data on the efficacy and safety of immune checkpoint inhibitor–based treatment in patients with unresectable stage III NSCLC whose cancer has not progressed following concurrent chemoradiation, Summarize other key clinical trials evaluating immunotherapies and immunotherapy-based combinatorial approaches in earlier stages of lung cancer, and available evidence from these trials, Identify appropriate patients with locally advanced, unresectable NSCLC who are candidates for immunotherapy as part of multimodal therapy for stage III disease, Implement an optimal multimodal treatment plan inclusive of concurrent chemoradiotherapy and consolidation immunotherapy for appropriate patients with stage III NSCLC, considering the latest evidence, indications, recommendations, and patient needs/preferences, Manage overlapping and non-overlapping adverse effects associated with immunotherapy, radiation therapy, and chemotherapy in patients with stage III NSCLC receiving consolidation therapy with a checkpoint inhibitor following chemoradiation

1hr 10mins

4 Nov 2019

Episode artwork

Roy H. Decker, MD, PhD - The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

58mins

28 Dec 2018

Most Popular

Episode artwork

Roy H. Decker, MD, PhD - The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

PeerView Clinical Pharmacology CME/CNE/CPE Video

The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

57mins

28 Dec 2018

Episode artwork

Roy H. Decker, MD, PhD - The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

58mins

28 Dec 2018